SCHEMBL1367154

SCHEMBL1367154

COc1ccc(CC(=O)c2cc3c(OC)cc(OC)cc3sc2=O)cc1

nearest known ligand 0.51

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
SMN1; SMN2 Q16637 4/20 0.51
NPC1 O15118 4/20 0.51
RAB9A P51151 3/20 0.51
HTT P42858 3/20 0.49
LMNA P02545 2/20 0.49
MEN1 O00255 1/20 0.47
ALDH1A1 P00352 1/20 0.47
CYP3A4 P08684 1/20 0.47
HPGD P15428 1/20 0.47
KMT2A Q03164 1/20 0.47
ATM Q13315 1/20 0.47
USP2 O75604 1/20 0.46
TP53 P04637 1/20 0.46
HSP90AA1 P07900 1/20 0.45
CSNK1D P48730 2/20 0.43
MAPT P10636 1/20 0.42
CASP3 P42574 1/20 0.40
CASP7 P55210 1/20 0.40
HIF1A Q16665 1/20 0.39
TUBB4A P04350 1/20 0.38

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL1369377 0.85 CYP3A4 (0.39) SMN1; SMN2NPC1RAB9ALMNAALDH1A1
SCHEMBL1369312 0.84 ALDH1A1 (0.44) SMN1; SMN2NPC1RAB9AHTTLMNA
SCHEMBL1368496 0.83 SMN1; SMN2 (0.51) SMN1; SMN2NPC1RAB9AHTTLMNA
SCHEMBL1366877 0.81 SMN1; SMN2 (0.45) SMN1; SMN2NPC1RAB9AHTTLMNA
SCHEMBL1366033 0.79 GSK3B (0.53) NPC1RAB9AHTTLMNAMEN1
SCHEMBL1366032 0.79 GSK3B (0.53) NPC1RAB9AHTTLMNAMEN1
SCHEMBL1368341 0.79 GSK3B (0.53) NPC1RAB9AHTTLMNAMEN1
SCHEMBL1366631 0.79 USP2 (0.56) SMN1; SMN2NPC1RAB9AHTTLMNA
SCHEMBL1369671 0.77 SMN1; SMN2 (0.61) SMN1; SMN2NPC1RAB9AHTTLMNA
SCHEMBL1367943 0.77 ABCG2 (0.60) SMN1; SMN2NPC1RAB9ALMNAMEN1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20090275650-A1 3-Acyl coumarins, thiochromones and quinolones and therapeutic uses thereof TEMPLE UNIVERSITY- OF THE COMMONWEALTH SYSTEM OF HIGHER EDUCATION (US) 2009-11-05 US claimed
WO-2006132947-A2 3-ACYL COUMARINS, THIOCHROMONES AND QUINOLONES AND THERAPEUTIC USES THEREOF TEMPLE UNIVERSITY- OF THE COMMONWEALTH SYSTEM OF HIGHER EDUCATION (US) 2006-12-14 WO claimed
US-8067461-B2 3-acyl coumarins, thiochromones and quinolones and therapeutic uses thereof TEMPLE UNIVERSITY-OF THE COMMONWEALTH SYSTEM OF HIGHER EDUCATION (US) 2011-11-29 US disclosed
US-20090275650-A1 3-Acyl coumarins, thiochromones and quinolones and therapeutic uses thereof TEMPLE UNIVERSITY- OF THE COMMONWEALTH SYSTEM OF HIGHER EDUCATION (US) 2009-11-05 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090275650-A1 3-Acyl coumarins, thiochromones and quinolones and therapeutic uses thereof NQO2, NQO1, HCCS SMN1; SMN2 4848/4885NPC1 338/4885RAB9A 1991/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.